Therapeutic IL-13 polypeptides
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsKenan Christopher Garcia, Ignacio Moraga Gonzalez
Life of this patent
Estimating the term…
Abstract
Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13Rα2, relative to the native human IL-13 protein; (b) altered affinity for IL-13Rα1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4Rα relative to the native human IL-13 protein.
Claims8
A nucleic acid encoding a polypeptide, wherein the polypeptide comprises a modified interleukin 13 (IL-13) polypeptide engineered to have (a) increased affinity for interleukin 13 receptor α2 (IL-13Rα2) relative to native human IL-13 protein;
- and (b) decreased affinity for interleukin 13 receptor α1 (IL-13Rα1) relative to native human IL-13 protein;
- wherein the modified IL-13 polypeptide comprises amino acid changes L10H, R86T, D87G, T88R, R108K relative to wild type IL-13.
Dependencies are inferred from the claim text.